ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Trimodality studies in pleural malignant pleural pneumonectomy

Trimodality studies in pleural malignant pleural pneumonectomy
Ref n Chemotherapy RR
(percent)		 EPP done
(percent)		 Mortality
(percent)		 Completed trimodal
(percent)		 OS (ITT) months OS: Subsets months PFS months
Weder[1] 19 32 84 0 68 23 NR CT + EPP: 16.5
Weder[2] 61 NR 74 2.2 59 19.8 CT + EPP: 23 CT + EPP: 13.5
Rea[3] 21 33 81 0 71 25.5 27.5 CT + EPP: 16.3
Flores[4] 21 26 42 0 42 19 CT + EPP + RT: 33.5 NR
Opitz[5] 63 32 – 3.2 – NR NR NR
Buduhan[6] 55 NR 84 4.3 69 NR CT + EPP: 24
TMT: 25		 NR
de Perrot[7] 60 NR 75 6.7 50 14 NR NR
Krug[8] 77 32 70 4 52 16.8 CT + EPP: 21.9
TMT: 29.1		 ITT: 10.1
CT + EPP: 18.3
Van Schil[9] 58 43 72 6.5 65 18.4 TMT: 33 ITT: 13.9
Rea[10] 54 29 83 NR 41 15.5 NR ITT PFS: 8.6
Bille[11] 25 NR 88 4 71 12.8 NR NR
Okada[12] 27 NR 100 3.7 63 13 23 (chemoRT after EPP) NR
RR: response rate; EPP: extrapleural pneumonectomy; OS: overall survival; PFS: progression free survival; CT: chemotherapy; TMT: trimodality therapy; ITT: intent to treat; NR: not recorded.
References:
  1. Weder W, et al. Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J Clin Oncol 22(17):3451, 2004.
  2. Weder W, et al. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol 18(7):1196, 2007.
  3. Rea F, et al. Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): Feasibility and results. Lung Cancer 57(1):89, 2007.
  4. Flores RM, et al. Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial. J Thorac Oncol 1(4):289, 2006.
  5. Opitz I, et al. Incidence and management of complications after neoadjuvant chemotherapy followed by extrapleural pneumonectomy for malignant pleural mesothelioma. Eur J Cardiothorac Surg 29(4):579, 2006.
  6. Buduhan G, et al. Trimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg 88(3):870, 2009.
  7. de Perrot M, et al. Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Clin Oncol 27(9):1413, 2009.
  8. Krug LM, et al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol 27(18):3007, 2009.
  9. Van Schil PE, et al. Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial. Eur Respir J 36(6):1362, 2010.
  10. Pasello G, et al. Pemetrexed plus carboplatin or cisplatin as neoadjuvant treatment of operable malignant pleural mesothelioma (MPM). Anticancer Res 32(12):5393, 2012.
  11. Bille A, et al: Induction chemotherapy, extrapleural pneumonectomy, and adjuvant radiotherapy for malignant pleural mesothelioma: experience of Guy's and St Thomas' hospitals. Gen Thorac Cardiovasc Surg 60(5):289, 2012.
  12. Okada K: Trimodality Therapy With Extrapleural Pneumonectomy, Radiation Therapy, And Chemotherapy For Malignant Pleural Mesothelioma. 11th International Conference of the International Mesothelioma Interest Group. 2012.
Graphic 88466 Version 3.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟